DelveInsight’s Obesity Pipeline Insight report offers exhaustive global coverage of available pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Obesity pipeline domain.
Some of the significant pointers taken from the Obesity Pipeline report:
Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight
The Obesity pipeline report lays down detailed profiles of the Obesity pipeline assets as well as the inactive and dormant Obesity drug assets, comparative analysis of clinical and non-clinical stage Obesity products, rich assessment of driving and restraining factors, along with the opportunities and risks in the Obesity pipeline landscape.
Obesity Overview
Obesity is a complex disorder that involves the accumulation of excessive amounts of fat in the body. It is a medical problem that is associated with the heightened risks of other health conditions such as diabetes, heart disease, cancers, high blood pressure, and other cardiovascular diseases. At present, Obesity has become a global concern causing the death of more than 4 million people each year.
Discover more about the disease, therapies, and Obesity pipeline activity @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight
Obesity Pipeline Drugs
Drug
Company
Phase
MoA
RoA
SCO-094
Scohia Pharma
Phase I
Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide 1 receptor agonists
Oral
ERX1000
ERX Pharmaceuticals
leptin sensitizer
AMG 171
Amgen
Undefined mechanism
NA
ALY688-SR
Allysta Pharmaceuticals
Adiponectin receptor agonists
Subcutaneous
EMP16-02
Empros Pharma
Phase II
Alpha-glucosidase inhibitors; Amylase inhibitors; Lipase inhibitors
IBI362
Innovent Biologics
Glucagon-like peptide 1 receptor agonists; Glucagon receptor agonists
BI 456906
Boehringer Ingelheim,
MEDI0382
MedImmune LLC,
Glucagon receptor agonists; Glucagon-like peptide 1 stimulants
Tirzepatide
Eli Lilly and Company
Phase III
PF-06882961
Pfizer
Glucagon-like peptide 1 receptor agonists
Obesity Therapeutics Assessment
The Obesity Pipeline report proffers a comprehensive picture of the novel Obesity pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
By Stage
By Route of Administration
By Molecule Type
By Mechanism of Action
By Targets
Scope of the Obesity Pipeline Report
For rich insights into emerging therapies and assessment, visit @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight
Table of Contents
1
Introduction
2
Executive Summary
3
Obesity: Overview
4
Pipeline Therapeutics
5
Late Stage Products (Phase III)
6
Mid Stage Products (Phase II)
7
8
Early Stage Products (Phase I/II)
9
Early Stage Products (Phase I)
10
Preclinical and Discovery Stage Products
11
Inactive Products
12
Therapeutic Assessment
13
14
Obesity Key Companies
15
Obesity Key Products
16
Obesity- Unmet Needs
17
Obesity- Market Drivers and Barriers
18
Appendix
19
About DelveInsight
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.
Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/obesity-pipeline-insight